BLACK DIAMOND THERAPEUTICS, INC. Unrealized Gain (Loss) on Derivatives
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Unrealized Gain (Loss) on Derivatives of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2021-03-25
- BLACK DIAMOND THERAPEUTICS, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-09-30 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-06-30 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-03-31 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. unrealized gain (loss) on derivatives for fiscal 2020 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. unrealized gain (loss) on derivatives for fiscal 2019 was -$6.39M.
- BLACK DIAMOND THERAPEUTICS, INC. unrealized gain (loss) on derivatives for fiscal 2018 was -$15.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | $23.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-11 | $0.00 10-Q · filed 2020-08-11 | $23.00K derived: sum of 3 quarters · filed 2021-03-25 | -$1.09M derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2021-03-25 | $23.00K derived: sum of 2 quarters · filed 2021-03-25 | -$1.09M derived: sum of 3 quarters · filed 2021-03-25 | -$6.39M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.09M derived: sum of 2 quarters · filed 2021-03-25 | -$6.39M derived: sum of 3 quarters · filed 2021-03-25 | -$6.39M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$1.12M 10-Q · filed 2020-11-10 | -$6.42M derived: sum of 2 quarters · filed 2020-11-10 | -$6.42M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$5.30M 10-Q · filed 2020-08-11 | -$5.30M 10-Q · filed 2020-08-11 | ||
| 2018-12-31 | -$15.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |